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Introduction: Synchronous oligometastatic (sOM) disease
is an oncological concept characterized by a limited cancer
burden. Patients with oligometastasis could potentially
benefit from local radical treatments. Despite the fact
that the sOM condition is well recognized, a universal
definition, including a specific definition for NSCLC, is not
yet available. The aim of this systematic review was to
summarize the definitions of and staging requirements
for use of the term synchronous oligometastatic in the
context of NSCLC.
Methods: The key issue was formulated in one research
question according to the population, intervention,
comparator, and outcomes strategy. The question was
introduced in MEDLINE (OvidSP). All articles dealing with
sOM NSCLC and providing a definition of synchronous oli-
gometastasis in NSCLC were selected and analyzed.
Results: A total of 21 eligible articles focusing on sOM
NSCLC were retrieved and analyzed. In 17 studies (81%),
patients had to be staged with magnetic resonance imaging
or computed tomography of the brain, thoracic and
abdominal computed tomography, and positron emission
tomography. The total number of metastases allowed in the
definitions ranged from one to eight, but in 38.1% of studiesthe maximum number was 5. Most of the publications did
not define the number of involved organs or the maximum
number of metastases per organ. For mediastinal lymphJournal of Thoracic Oncology Vol. 14 No. 12: 2053-2061
2054 Giaj-Levra et al Journal of Thoracic Oncology Vol. 14 No. 12node involvement, only five articles (27.8%) counted this as
a metastatic site.
Conclusions: No uniform definition of sOM NSCLC could be
retrieved by this systematic review. However, extended
staging was mandated in most of the studies. An accepted
oncological definition of synchronous oligometastasis is
essential for patient selection to define prospective clinical
trials.
 2019 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: NSCLC; Oligometastatic disease definition; Syn-
chronous; Systematic reviewIntroduction
Approximately half of all patients with NSCLC present
with metastatic disease, with a median overall survival
(OS) of 12 months.1 However, metastatic NSCLC is a
heterogeneous status, characterized by different clinical
presentations and prognoses according to anatomical
site and number of metastases. In 1995, Hellman and
Weichselbaum defined oligometastatic disease2 as a
state of limited systemic metastatic burden in which
eradication of oligometastases with local radical thera-
pies (i.e., surgery and radiotherapy) could be curative in
selected patients.3
Currently, no single, uniform, and reliable definition
of synchronous oligometastatic (sOM) disease in NSCLC
exists. In the European Society for Medical Oncology
guidelines a paragraph is dedicated on oligometastatic
disease, without a clear definition of this status,Figure 1. Searcreporting that many clinical trials investigating local
treatment of oligometastatic disease have limited inclu-
sion to patients with no more than five metastases, but
the vast majority of the trials have included patients with
no more than three metastases.1 In the National
Comprehensive Cancer Network guidelines patients with
oligometastasis are defined as those with isolated or
limited metastatic disease.4
A uniform definition is of importance as new effective
local ablative therapies are developed. Their integration
in therapeutic algorithms for sOM NSCLC has been tested
in different prospective clinical trials.5,6
In an attempt to provide a definition of sOM NSCLC,
the European Organization for Research and Treatment
of Cancer (EORTC) Lung Cancer Group (LCG) developed
a consensus definition based on clinical cases of sOM
disease, a European survey on sOM disease, and a sys-
tematic review of the currently requested staging
methods and definitions of the term synchronous oligo-
metastatic used in clinical trials.7–9 Here we report the
results of the systematic review.
Materials and Methods
The key issue was formulated in one question
according to the population, intervention, comparator,
and outcomes criteria (population, intervention, con-
trol, and outcomes). The standard reporting guidelines
(Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statement [http://www.prisma-
statement.org/]) has been used for this systematic re-
view. The research question was concentrated strictly
on the clinical definition of sOM NSCLC. The research
equation composed of Medical Subject Headingsh flowchart.
Table 1. Studies Selected, Population, and Intervention in Synchronous Oligometastatic NSCLC (PICO Criteria)
Authors/Year
Population Intervention
Type of
Study
Single-
Center/
Multicenter
Patients,
n
TNM
Edition Work-up PET-CT
Brain
MRI
Brain
CT
Mediastinal
Staging
Pathological
Proof of
Malignancy
Downey et al.
(2002)27
NRT Single 23 Fifth Complete No Yes NA EBUS All sites
Khan et al.
(2006)12
RS Single 23 NA Partiala Yes NA NA PET-CT NA
Inoue et al.
(2010)22
RS Single 25 NA Complete No No NA PET-CT No
Cheruvu et al.
(2011)23
RS Single 38 Seventh Complete Yes Yes NA PET-CT NA
Collaud et al.
(2012)24
RS Single 29 Sixth Complete Yes Yes NA EBUS NA
Congedo et al.
(2012)25
RS Single 53 Fifth Complete Yes No Yes EBUS NA
De Ruysscher
et al.
(2012)26
NRT Single 40 Sixth Complete Yes Yes NA PET-CT 1 site
Lopez Guerra
et al.
(2012)13
RS Single 78 Sixth Incomplete NA NA NA NA NA
Griffioen et al.
(2013)28
RS Multicenter 61 Fifth-seventh Complete Yes Yes NA PET-CT NA
Nieder et al.
(2014)14
RS Multicenter 23 Seventh Complete Yes Yes Yes PET-CT NA
Parikh et al.
(2014)15
C Single 186 Seventh Complete Yes Yes No PET-CT NA
Sheu et al.
(2014)18
DB Single 90 Seventh Incomplete NA NA NA NA No
Plones et al.
(2015)16
RS Single 56 Sixth Complete Yes Yes Yes EBUS NA
Su et al.
(2015)20
NRT Multicenter 198 Sixth Complete Yes Yes Yes PET-CT NA
Xanthopoulos
et al.
(2015)21
DB Single 29 Seventh Complete Yes NA No PET-CT NA
Fleckenstein
et al.
(2016)29
DB Single 39 Fifth-seventh Complete Yes NA NA NA NA
Gomez et al.
(2016)6
RT Multicenter 49 Seventh Complete Yes Yes NA PET-CT NA
Johnson et al.
(2016)11
DB Single 37 Fifth-seventh Complete Yes Yes Yes EBUS No
Sakai et al.
(2016)17
RS Single 18 Seventh Complete Yes Yes Yes PET-CT NA
Su et al.
(2016)20
NRT Single 91 Sixth Complete Yes Yes Yes PET-CT NA
Iyengar et al.
(2018)5
RT Single 29 NA Completeb Yes Yes Yes PET-CT 1 site
aPET (or thorax þ abdomen CT and bone scan) without brain MRI/CT.
bBrain MRI/CT þ PET (or thorax þ abdomen CT and bone scan).
PICO, population, intervention, comparator, and outcomes; PET, positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging;
NRT, no randomized trial; EBUS, endobronchial ultrasound; NA, not available, RS, retrospective series; C, cohort; DB, database.
December 2019 Defining Synchronous Oligometastatic NSCLC 2055descriptors and free text keywords, as reported in
Supplement Table 1, was launched in MEDLINE
(OvidSP) in October 2017.
A time cutoff of January 1, 1996, has been used to
identify publications with patients staged according tothe fifth and later TNM classifications.10 Titles and
abstracts were screened independently by two authors
(M. G. L. and N. G. L.) and reviewed by two other authors
(A. M. D. and T. B.) to determine potentially relevant
articles for the systematic review. The selection process
Table 2. Outcomes in NSCLC Synchronous Oligometastatic (PICO criteria)
Authors/Year
Outcomes
Organs
with
1 Mts,
n
Mts,
n
Mts per
organ,
n
N status
as
organ/N
level
Prognostic
Factor
Analysis
Primary
Outcome
Multivariate
Analysis and OS
Metastatic
Site
Excluded
Mutational
Analyses
/Impact on
Outcomes
Curative
Intent
Downey et al. (2002)27 1 1 1 No No Other — No No NA
Khan et al. (2006)12 NA 2 ND Yes/N3 No OS None No No Yes
Inoue et al. (2010)22 2 5 ND No Yes OS/PFS/
Other
None No No Yes
Cheruvu et al.
(2011)23
NA 8 ND Yes/N3 Yes OS GTV No No Yes
Collaud et al. (2012)24 1 1 1 No Yes OS None No Yes (EGFR)/
No
Yes
Congedo et al.
(2012)25
2 2 2 No Yes OS Weight loss, PET-CT,
surgical resection
No No NA
De Ruysscher et al.
(2012)26
NA 5 ND No No OS None Pleural or
pericardial
effusion
Yes (EGFR)/
NA
Yes
Lopez Guerra et al.
(2012)13
NA 4 ND No Yes OS Radiation dose, PS,
tumor volume
No No Yes
Griffioen et al.
(2013)28
NA 3 ND No Yes OS/PFS/
Other
None No No Yes
Nieder et al. (2014)14 1 3 3 No Yes OS None No No Yes
Parikh et al. (2014)15 NA 5 ND Yes/N3 Yes OS PS, N status, number
of organs,
No Yes (EGFR)/
Yes
Yes
Sheu et al. (2014)18 NA 3 ND NA Yes OS/PFS Sex, PS, local therapy No No Yes
Plones et al. (2015)16 NA 5 ND No Yes OS Bone mts No No Yes
Su et al. (2015)20 3 NA 2 liver
Mts
No Yes OS Radiation dose (>63
Gy),
tumor volume, PS
No Yes (EGFR)/
No
Yes
Xanthopoulos et al.
(2015)21
NA 4 ND No Yes OS Radiotherapy, female,
number of metastatic
organs
No No Yes
Gomez et al. (2016)6 NA 3 ND Yes/N3 No PFS — No Yes (EGFR/
ALK)
/Yes
Yes
Fleckenstein et al.
(2016)29
NA 5 3 for
brain
Mts
NA Yes OS/PFS None No No Yes
Johnson et al.
(2016)11
2 5 <5 No No OS None No No Yes
(continued)
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December 2019 Defining Synchronous Oligometastatic NSCLC 2057was divided into two parts: selection of abstracts and
selection of full articles.
Abstracts were selected if they (1) focused only on
lung cancers (NSCLC or SCLC), (2) dealt with sOM tu-
mors, whatever the definition used by the authors, (3)
provided a definition of oligometastatic status, (4)
were a retrospective or prospective study, and (5) in
the case of retrospective studies, the number of pa-
tients was at least 14 (adapted from the statistical
Simon’s design).
Full articles were evaluated according to the previous
criteria, and contributions in French, English, Dutch, and
Italian were accepted.
Series focusing on a specific single metastatic organ
(e.g., brain only or adrenal gland only) were excluded,
as the focus of the review was oligometastasis instead
of solitary metastasis. Also, systematic reviews, meta-
analysis, and editorials were not included.
Additional publications were identified through
examination of references cited in the eligible publi-
cations and were added if they also fulfilled the
selection criteria. Disagreements were resolved by
consensus.
The following variables were extracted from the
publications for the definition of the sOM NSCLC: (1)
number of metastases, (2) number of organs with at
least one metastasis, (3) number of metastases per or-
gan, (4) lymph node status, and (5) metastatic sites that
were excluded.
Additional data describing the population, interven-
tion, and outcomes were also extracted: (1) type of
study; (2) single-center or multicenter experience; (3)
number of patients enrolled; (4) staging system; (5)
radiological assessment (thoracic, mediastinal, cranial,
and extracranial metastatic staging); (6) pathological
proof of malignancy; (7) primary outcome; and (8)
curative therapeutic intent.
Results
The search strategy and potentially eligible abstracts
are shown in Supplement Table 2. A total of 1125
potentially eligible titles were identified and 80 duplicates
were removed. Among 1045 titles, 348 respected the
abstract selection criteria and another nine articles were
added by reviewing the references from the included ar-
ticles. A total of 73 articles fulfilled the publication se-
lection criteria, and among them we selected those that
were focused on the sOM condition (i.e., articles focusing
only on oligoprogression and oligorecurrence were
excluded). We accepted articles if they evaluated both
sOM disease (the main issue of the systematic review)
and oligoprogression/recurrence. A total of 21 articles
were eligible for this systematic analysis,5,6,11–28 as
reported in Figure 1.
Table 3. Summary of Variables
Variables
Publications (%)
(N ¼ 21)
Type of study, n (%)
Retrospective series 10 (47.6%)
Prospective nonrandomized study 4 (19%)
Randomized study 2 (9.6%)
Cohort 1 (4.8%)
Database/registry 4 (19%)
Other 0
Single center 17 (81%)
Multicentric 4 (19%)
Total patients (in all the studies
combined)
1215 (range 18–
198)
Median no. of patients 39
Staging system, n, (%)
Fifth or sixth 8 (38.1%)
Sixth and seventh 3 (14.3%)
Seventh 7 (33.3%)
Eighth 0
Not available 3 (14.3%)
Work-up, n (%)
Brain MRI/CT þ PET (or thoracic þ
abdominal CT and bone scan), (%)
17 (81%)
PET (or thoracic þ abdominal CT and
bone scan) w/o MRI/CT
1 (4.8%)
Incomplete work-up 3 (14.2%)
PET-CT, n (%)
No 2 (9.5%)
Yes 17 (81%)
Not reported 2 (9.5%)
Brain MRI, n (%)
No 2 (9.5%)
Yes 13 (61.9%)
Not reported 6 (28.6%)
Brain CT, n (%)
No 2 (9.5%)
Yes 7 (33.4%)
Not reported 12 (57.1%)
Mediastinal staging, n, (%)
PET 13 (62%)
CT only 0 (0%)
EBUS or EUS or mediastinoscopy 5 (23.8%)
Not reported/not assessed 3 (14.2%)
Organs with at 1 metastasis, n, (%)
1 3 (14.3%)
2 4 (19%)
3 1 (4.8%)
Any 5 (23.8%)
NA 8 (38.1%)
Mediastinal lymph nodes are
counted as an organ, n, (%)
No 12 (51.1%)
Yes 6 (28.6%)
Not define 3 (14.3%)
Volume is considered to be an issue, n,
(%)
No 8 (38.1%)
Yes 5 (23.8%)
Not assessed 8 (38.1%)
(continued)
Table 3. Continued
Variables
Publications (%)
(N ¼ 21)
Primary outcome measure, n (%)
OS 14 (66.7%)
PFS 2 (9.5%)
Response 0 (0%)
QoL 0 (0%)
Other/multiple 5 (23.8%)
Pathological proof of metastasis, n (%)
No 3 (14.3%)
Systematic for all sites 1 (4.8%)
Systematic for 1 site 2 (9.5%)
Not reported 15 (71.4%)
Curative therapeutic intent, n (%)
No 1 (4.8%)
Yes 18 (85.7%)
Not reported 2 (9.5%)
Mutational status is considered, n, (%)
No 15 (71.4%)
Yes 6 (28.6%)
Mutational status analyzed, n
EGFR 4
ALK 0
Combination (EGFR/ALK) 2
MRI, magnetic resonance imaging; CT, computed tomography; PET, positron
emission tomography; EBUS, endobronchial ultrasound; endoscopic ultra-
sound, NA, not available; OS, overall survival; PFS, progression-free survival;
QoL, quality of life; ALK, ALK receptor tyrosine kinase gene.
2058 Giaj-Levra et al Journal of Thoracic Oncology Vol. 14 No. 12Population
The main studies’ characteristics are reported in
Table 15,6,11–18,20–26,28 Most of the published data were
retrospective (n ¼ 14 [66.6%]) and from a single center
(n ¼ 17 [81%]). The total number of patients with sOM
NSCLC described in the 21 studies was 1215 (range 18–
198), with a median number of 39.Mandated Staging
In most of the studies (n ¼ 17 [81%]), staging with
thoracic and abdominal computed tomography (CT) scan,
positron emission tomography with fludeoxyglucose F 18
integrated with CT (18F-FDG PET/CT), and brain magnetic
resonance imaging (MRI) or CT was mandated. In
particular, in 16 studies baseline brain imaging was
mandated and baseline brain MRI was preferred in 14
articles (66.7%). Mediastinal staging was predominantly
clinical (n ¼ 13 [62%]) with 18F-FDG PET/CT, with only
five articles (23.8%) mandating a pathological mediastinal
staging by endobronchial ultrasound. A pathological proof
of metastases was not requested in three articles (14.3%)
but was mandated for all sites in one study (4.8%) and for
at least one metastatic site in two studies (9.5%). In most
studies (n ¼ 15 [71.4%]) this information was not
available (Table 1).
December 2019 Defining Synchronous Oligometastatic NSCLC 2059Outcomes
The main information about the applied definitions of
sOM NSCLC is reported in Table 2.5,6,11–18,20–29 The total
number of metastases used in the definition of sOM
disease ranged from one to eight, and in eight studies
(38.1%) the maximum number of metastases allowed
was 5. In most of the series (n ¼ 13 [61.9%]), we did not
find any limitation or restriction about the number of
organs involved with at least one metastasis; otherwise,
when defined, the maximum number of allowed meta-
static organs was 3 in one article (4.8%), 2 in four ar-
ticles (19%), and 1 in three articles(14.3%).
The maximum number of metastases per organ was
not defined in 12 articles (51.1%), and in three (14.3%)
a partial definition was given (e.g., no more than two
liver metastases, no more than three metastases for the
brain, fewer than five in a single organ other than lung).
When a maximum number of metastases per organ was
defined, it ranged from one to five (six articles [28.6%]).
We checked whether mediastinal lymph nodes
involvement was counted as a separate metastatic site.
This was not specified in three studies (14.3%), in 13
studies (61.9%) lymph node involvement was not
counted in the number of metastatic organs allowed, and
in only five studies (23.8%) were mediastinal lymph
nodes effectively counted as a metastatic site. In one
article, all lymph nodal sites were considered to be
metastatic sites, whereas in four articles only the N3
stations were counted as a metastatic site.
Of the 21 studies, 19 did not exclude any specific
metastatic site, whereas in two articles uncontrolled
brain, gastrointestinal, and skin metastases or pleural/
pericardial metastases were not allowed.
OS was the primary outcome in most of the published
articles (n ¼ 18 [85.7%]), whereas in two articles (9.5%)
it was progression free-survival (PFS). In four articles
both OS and PFS were considered to be coprimary end
points. In 18 articles (85.7%) the authors declared that
the treatment of oligometastatic disease had a curative
intent. All of the variables have been summarized in
Table 2.Discussion
Despite the fact that the sOM status is currently
recognized in NSCLC, a uniform definition is not avail-
able and several issues are still open. Hence, we have
performed a systematic review of the literature to offer
scientific support on the published definitions of sOM
NSCLC and to support the EORTC LCG consensus.8 On
the basis of this systematic review, it emerges that a
single clinical definition of sOM NSCLC does not exist; of
the numerous retrieved publications on sOM disease,
only a minority provided a clear definition (Table 3).Although there is no clear definition of sOM disease,
in most of the articles a complete radiological staging
using brain MRI and 18F-FDG PET/CT was mandated.
This is in line with the general consensus in scientific
societies such as the European Society for Medical
Oncology, National Comprehensive Cancer Network, and
EORTC.1,4,30 Complete radiological staging remains
important for the definition of sOM disease, but also the
outcome of radical treatment of patients with sOM dis-
ease, as stage migration is a well-known phenomenon
when introducing more sensitive diagnostic techniques
as 18F-FDG-PET/CT and brain MRI. Potentially, this could
be useful in better patient selection and, consequently,
improvement in clinical outcomes.
Furthermore, 18F-FDG PET/CT was the main method
required to stage both systemic disease and mediastinal
lymph node status. On the other hand, it is unclear
whether pathological proof of mediastinal lymph node
involvement in the metastatic process is necessary in
addition to the metabolic and morphologic assessment,
probably because of excellent sensitivity and specificity
of 18F-FDG PET/CT. A recent systematic review reported
that 18F-FDG PET/CT is associated with a sensitivity and
specificity in the identification of lymph node involve-
ment with a value between 79% and 85% and between
87% and 92%, respectively.31
In most articles, the authors did not report on the
histopathologic proof of malignancy of the metastatic
site. Apparently, mediastinal lymph node involvement is
not uniformly considered relevant in the definition of
sOM NSCLC or in the selection of patients eligible for
combined local and systemic treatments. It is also un-
certain whether involved mediastinal lymph nodes
should be counted as a separate metastatic site. Ac-
cording to the TNM classification,10 mediastinal lymph
nodes are considered locally advanced but not meta-
static. However, from the available literature it is known
that mediastinal lymph node involvement negatively af-
fects the outcome of patients with sOM disease.10 In
most of the studies included in this systematic review,
mediastinal lymph node involvement was not counted as
a separate metastatic anatomical site. Future prospective
trials should establish or evaluate whether radical
treatment of sOM NSCLC with mediastinal lymph node
involvement is recommended and which levels (N1–N3)
have an impact on outcomes of these patients.
Additionally, in all the included articles, we could not
identify any specific metastatic site that was uniformly
excluded from a radical combined oncological approach.
This could be a selection bias, as some clinical pre-
sentations (e.g., leptomeningeal dissemination, lung
lymphangitis) are associated with poor clinical outcomes
and those patients have not been considered in
the selected, mostly retrospective, studies for this
2060 Giaj-Levra et al Journal of Thoracic Oncology Vol. 14 No. 12review because they are generally not included in trials
involving sOM disease.
The level of evidence and the potential biases of the
retrieved publications can limit the information pro-
vided by this review. The majority of the studies were
retrospective single-center series, and outside of the
maximum number of metastases, other information
such as the number of organs with at least one metas-
tasis, the maximal number of metastases per organ was
a selection criteria in only a limited number of publi-
cations. Even for the maximal number of metastases,
which was defined in all studies, no clear cutoff could
be found; however, most of the studies did not allow
more than five metastases. From the published papers
we cannot deduce whether these data were missing or
the authors had not considered them fundamental for
their research.
Conclusions
Synchronous oligometastatic NSCLC refers to NSCLC
in which the combination of systemic and local ablative
treatments may influence tumor behavior. Although
many studies have been published on this subject, the
evidence from this systematic review suggests that a
uniform and reliable definition of sOM disease does not
exist. However, mandated diagnostic staging was very
stringent with 18F-FDG PET/CT and imaging of the brain.
Nevertheless, some consensus emerged in the cutoff
defining the maximal number of metastases and the
staging work-up.
The results of this systematic review served as a
scientific basis for the consensus meeting on the defini-
tion of sOM disease, as initiated by the EORTC LCG, to
propose a collective multidisciplinary definition of sOM
NSCLC for use in prospective clinical trials.
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